Abstract: As an example, in some embodiments is a dressing that may comprise a manifold, a bioresorbable component, and a degradation-modulating component. The degradation-modulating component may cover two or more surfaces of the bioresorbable component. The degradation-modulating component may be further configured to modulate degradation of the bioresorbable component.

Abstract: The present invention relates to a dosage form comprising at least one functionalized calcium carbonate-comprising material (FCC) and at least one hot melt extruded polymer resin, a method for producing same, a pharmaceutical, nutraceutical, cosmetic, home and personal care product comprising the dosage form and the uses thereof.

Abstract: Nanoparticles comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer and compositions, especially topical compositions, comprising the nanoparticles. The compositions can be used as topical formulations for ameliorating pain, including for diabetic patients with peripheral neuropathy.

Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.

Abstract: Anhydrous hydrocolloid matrices contain one or more encapsulated therapeutic agents, including an acne agent and/or skin conditioning agent. The anhydrous hydrocolloid matrices are used as acne treatment dressings alone or in a laminate with a water-impermeable or semi-water impermeable backing and a release liner. The anhydrous hydrocolloid matrices are made using a premix of viscosity modifiers and hydrocarbon emollients and the one or more therapeutic agents, which are mixed via high shear mixing to form the premix. The resulting anhydrous hydrocolloid matrices include the one or more therapeutic agents which are encapsulated and homogeneously distributed therein.

Abstract: The present disclosure relates to a dry process for preparing a solid pharmaceutical dosage form of vitamin K1 comprising: a) blending vitamin K1 with a first diluent under a first set of pre-determined conditions to obtain a first mixture; b) contacting the first mixture with a second diluent under a second set of pre-determined conditions to obtain a second mixture; c) mixing the second mixture with the excipients selected from a group consisting of disintegrant, lubricant and glidant under a third set of pre-determined conditions to obtain a third mixture; and d) compressing or encapsulating the third mixture to obtain the solid pharmaceutical dosage form of vitamin K1.

Abstract: The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure.

Abstract: Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.

Abstract: Devices for local delivery of tacrolimus or a derivative thereof are provided, wherein the devices comprise a polymeric matrix containing tacrolimus or a derivative thereof that provides for delayed and extended release of tacrolimus or a derivative thereof. The devices can locally deliver tacrolimus or a derivative thereof to injured nervous system tissue upon implantation in a subject. Thus, techniques for local delivery of tacrolimus or a derivative thereof and methods of treatment using such devices are also provided.

Abstract: A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.

Abstract: Systems and methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and preprogrammable transdermal or other drug administration system.

Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

Abstract: The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

Abstract: The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.

Abstract: This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

Abstract: This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

Abstract: A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.

Abstract: The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and/or diminishing fever or pain.

Abstract: The present disclosure relates to leave-on hair styling compositions, and to methods for styling hair using the compositions. The leave-on hair styling compositions include: (a) pullulan; (b) one or more cellulose ethers; (c) one or more water-soluble solvents; and (d) water. The leave-on hair styling compositions are unique in that they impart durable styling or shaping benefits, volume and fullness, smoothness, shine, texture, control fizziness, and provide overnight style, without the need for silicones and/or synthetic film forming polymers.

Abstract: The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention.